1. A patient with known malignant hyperthermia susceptibility requires emergency intubation. Succinylcholine is contraindicated. The team gives rocuronium 1.2 mg/kg and achieves intubating conditions in 50 seconds. Thirty seconds after intubation, the surgeon declares the procedure unnecessary and the patient must be extubated immediately. The anesthesiologist reaches for the reversal agent. Which of the following correctly integrates the pharmacological rationale for the agent and dose chosen?

• A) Neostigmine 0.07 mg/kg with glycopyrrolate should be given immediately — at 1.2 mg/kg rocuronium the block is deep but not profound, and the maximum dose of neostigmine generates sufficient acetylcholine to competitively displace rocuronium from the majority of end-plate receptors within 3 to 5 minutes, restoring the train-of-four ratio above 0.9.
• B) Sugammadex 4 mg/kg is the correct choice — this dose is approved for reversal of deep block defined as a train-of-four count of zero, and the 1.2 mg/kg rocuronium dose produces deep but not profound block; the higher 16 mg/kg dose is reserved only for sugammadex given before any rocuronium has reached the neuromuscular junction.
• C) Sugammadex 2 mg/kg is appropriate because the block is only minutes old and rocuronium has not yet fully equilibrated into peripheral tissue compartments; early post-injection reversal requires less sugammadex than reversal of established block because a larger proportion of the drug is still in the central plasma compartment and accessible to cyclodextrin encapsulation without deep biophase concentration to overcome.
• D) Sugammadex 16 mg/kg is required — the 1.2 mg/kg RSI dose of rocuronium produces profound neuromuscular block with a train-of-four count of zero and post-tetanic count approaching zero; neostigmine cannot reverse this depth of block under any circumstances, and sugammadex 16 mg/kg reliably reverses even this profound block within approximately 3 minutes, making the rocuronium-sugammadex pairing the only viable RSI strategy when succinylcholine is contraindicated and immediate reversibility must be guaranteed.
• E) No reversal agent is needed or appropriate — at 1.2 mg/kg, rocuronium's lipophilicity ensures that spontaneous redistribution from the neuromuscular junction back into the plasma occurs within 4 to 6 minutes, restoring adequate spontaneous ventilation without pharmacological intervention faster than any reversal agent can act.

2. An anesthesiologist maintains general anesthesia with sevoflurane, a volatile halogenated anesthetic agent, throughout a 3-hour abdominal procedure. She notices that the same maintenance dose of rocuronium that previously sustained moderate block for 35 minutes is now sustaining block for over 55 minutes without additional dosing. Which of the following best explains the mechanism by which volatile anesthetics potentiate non-depolarizing neuromuscular block, and what clinical adjustment does this interaction require?

• A) Volatile anesthetics potentiate non-depolarizing block through two complementary mechanisms: enhanced postjunctional sensitivity of the nicotinic acetylcholine receptor (reducing the number of unblocked receptors needed to trigger an action potential) and reduced presynaptic acetylcholine release from the motor nerve terminal; together these effects shift the dose-response curve of non-depolarizing agents leftward, meaning that lower plasma concentrations produce equivalent or deeper block; clinically, maintenance doses of non-depolarizing agents should be reduced and dosing intervals extended when volatile anesthetics are used, and reversal requirements may be altered.
• B) Volatile anesthetics potentiate non-depolarizing block by inhibiting plasma pseudocholinesterase activity in the systemic circulation, reducing the rate of spontaneous succinylcholine hydrolysis; this mechanism is specific to succinylcholine-based maintenance techniques and does not apply to rocuronium or other aminosteroid agents whose elimination is hepatic rather than enzymatic.
• C) Volatile anesthetics potentiate non-depolarizing block by competitively occupying the nicotinic acetylcholine receptor at the same binding site as non-depolarizing agents; the combined occupancy of the anesthetic and the non-depolarizing blocker produces additive receptor blockade, and the clinical implication is that the non-depolarizing agent dose should be reduced by exactly 50% when volatile anesthetics are co-administered.
• D) Volatile anesthetics reduce hepatic blood flow by approximately 30%, directly impairing rocuronium elimination and raising steady-state plasma concentrations during prolonged anesthesia; the potentiation is therefore entirely a pharmacokinetic phenomenon and is reversed immediately when the volatile agent is discontinued and hepatic blood flow normalizes.
• E) Volatile anesthetics potentiate non-depolarizing block by activating skeletal muscle GABA-A receptors that are expressed at low density in the perijunctional zone, producing chloride-mediated membrane hyperpolarization that raises the threshold for action potential propagation and reduces the concentration of unblocked receptors required to prevent neuromuscular transmission.

3. A patient undergoing bowel resection receives gentamicin irrigation of the peritoneal cavity for infection prophylaxis late in the procedure. Within 10 minutes, the anesthesiologist notes an unexpected deepening of neuromuscular block — the train-of-four count drops from 3 to 0 despite no additional neuromuscular blocking agent having been given. Neostigmine is administered but produces only partial and transient reversal. Which of the following correctly identifies the mechanism by which aminoglycoside antibiotics potentiate non-depolarizing neuromuscular block and explains the incomplete neostigmine response?

• A) Aminoglycosides competitively antagonize acetylcholine at the postjunctional nicotinic receptor, occupying the agonist binding site and directly blocking channel opening; the incomplete neostigmine response reflects the purely competitive nature of this antagonism, which is overcome only when acetylcholine concentration exceeds the aminoglycoside concentration — a ratio difficult to achieve at the peritoneal drug levels produced by irrigation.
• B) Aminoglycosides inhibit plasma pseudocholinesterase, reducing the rate of succinylcholine hydrolysis; because succinylcholine's depolarizing block had not fully resolved before the non-depolarizing agent was given in this case, the aminoglycoside has maintained a residual depolarizing component that neostigmine cannot reverse and may worsen.
• C) Aminoglycosides inhibit presynaptic voltage-gated calcium channels at the motor nerve terminal, reducing calcium-dependent acetylcholine vesicle fusion and release; because both aminoglycoside-induced block and non-depolarizing block depend on reduced acetylcholine availability or activity at the end plate, their effects are synergistic; neostigmine provides only partial reversal because it acts by inhibiting acetylcholine breakdown — it cannot compensate for severely reduced acetylcholine release caused by the presynaptic calcium channel blockade.
• D) Aminoglycosides produce their block by chelating calcium ions in the synaptic cleft, preventing calcium from diffusing to the motor nerve terminal where it is required for acetylcholine release; the chelated calcium-aminoglycoside complex also directly precipitates on the postjunctional membrane, mechanically occluding the nAChR ion channel pore in a manner that neostigmine cannot displace.
• E) Aminoglycosides potentiate non-depolarizing block by inhibiting the sodium-potassium ATPase in the muscle fiber membrane, reducing the resting membrane potential of the sarcolemma and thereby lowering the threshold current required for a given degree of nAChR block to prevent action potential propagation; neostigmine is ineffective because the sodium-potassium ATPase inhibition is not reversed by increased acetylcholine concentrations.

4. A 52-year-old man is on day 3 of mechanical ventilation for septic shock complicated by acute respiratory distress syndrome (ARDS). He has a MAP of 58 mmHg on norepinephrine, a creatinine of 3.8 mg/dL indicating acute kidney injury, and transaminases twice the upper limit of normal indicating hepatic involvement. The intensivist decides to initiate neuromuscular blockade to facilitate lung-protective ventilation. Both atracurium and cisatracurium are available. Which of the following correctly integrates the pharmacological arguments for preferring cisatracurium over atracurium in this specific patient?

• A) Cisatracurium is preferred because it undergoes renal elimination rather than Hofmann degradation, and in a patient with acute kidney injury the prolonged renal retention of cisatracurium paradoxically reduces the infusion rate needed to maintain block — lowering total drug exposure and therefore reducing laudanosine generation compared to atracurium, which relies on Hofmann degradation that is accelerated by the metabolic acidosis of septic shock.
• B) Cisatracurium is preferred because it is an aminosteroid agent reversible by sugammadex, whereas atracurium is a benzylisoquinolinium that cannot be reversed pharmacologically; in a hemodynamically unstable patient, the ability to immediately reverse neuromuscular block if the patient deteriorates is a critical safety advantage.
• C) Cisatracurium is preferred because its longer context-sensitive half-time means plasma concentrations decline more slowly after infusion discontinuation, reducing the risk of light planes of sedation from abrupt drug offset that could trigger sympathetic surges and worsen hemodynamic instability in a vasopressor-dependent patient.
• D) Cisatracurium is preferred because atracurium undergoes Hofmann elimination that is accelerated by the alkalosis of hyperventilation used in lung-protective ventilation, unpredictably shortening atracurium duration and requiring frequent dose adjustments; cisatracurium's predominantly renal elimination is unaffected by changes in pH produced by ventilator management.
• E) Cisatracurium is preferred over atracurium in this patient for three integrated reasons: it produces substantially less histamine release at clinical doses, which is critical in a patient already hemodynamically unstable on vasopressors where additional histamine-mediated vasodilation could precipitate cardiovascular collapse; it generates less laudanosine per unit time because of its higher potency requiring lower drug mass per hour; and its Hofmann elimination is entirely organ-independent, providing predictable duration despite the combined hepatic and renal dysfunction that would cause aminosteroid accumulation and unpredictable prolonged block.

5. A 28-year-old woman at 31 weeks gestation is receiving magnesium sulfate intravenously at 2 g/hour for preeclampsia with severe features. She requires emergency cesarean delivery under general anesthesia. The anesthesiologist plans to use succinylcholine 1.5 mg/kg for RSI and rocuronium for maintenance. She anticipates that both agents may behave unexpectedly in this patient. Which of the following correctly explains the mechanism by which hypermagnesemia from therapeutic magnesium infusion potentiates neuromuscular block from both depolarizing and non-depolarizing agents?

• A) Magnesium is a competitive antagonist at the postjunctional nicotinic acetylcholine receptor — it occupies the agonist binding sites with moderate affinity, reducing the number of receptors available for acetylcholine activation; because succinylcholine and non-depolarizing agents both depend on receptor availability to produce block, magnesium's competitive occupancy amplifies the effect of both agent classes symmetrically.
• B) Magnesium competes with calcium at presynaptic voltage-gated calcium channels in the motor nerve terminal, reducing calcium influx during action potential depolarization and thereby diminishing acetylcholine vesicle fusion and release; reduced acetylcholine availability at the synapse potentiates both depolarizing block (where the initial depolarization depends on available ACh-independent receptor activation by succinylcholine, but the Phase I-to-Phase II transition and the amplitude of fasciculations are affected) and non-depolarizing block (where competitive displacement becomes easier when less competing acetylcholine is released per stimulus), and clinically requires dose reduction for both agent classes and heightened vigilance for residual block postoperatively.
• C) Magnesium chelates calcium ions in the synaptic cleft, creating a calcium-deficient microenvironment immediately adjacent to the end plate; the calcium-magnesium chelates coat the postjunctional membrane, physically blocking ion channel access and producing a mechanical barrier to nAChR activation that is additive with both depolarizing and non-depolarizing pharmacological block.
• D) Magnesium inhibits acetylcholinesterase at the neuromuscular junction, raising synaptic acetylcholine concentrations; paradoxically, the elevated acetylcholine produces persistent end-plate depolarization that desensitizes the nAChR, rendering both depolarizing and non-depolarizing agents more effective because they are acting on a receptor already partially inactivated by high endogenous agonist concentration.
• E) Magnesium activates presynaptic GABA-B receptors on motor nerve terminals, producing retrograde inhibitory signaling that reduces the frequency of action potential propagation from the spinal cord to the neuromuscular junction; by reducing the number of nerve stimuli reaching the terminal per unit time, therapeutic magnesium effectively lowers the neuromuscular reserve and reduces the concentration of both agent classes required to produce complete block.

6. An anesthesiologist must determine whether a patient who received a large cumulative succinylcholine dose is in Phase I or Phase II block before deciding whether to administer neostigmine. She applies train-of-four stimulation and notes: TOF count of 4 with significant fade (the fourth twitch is approximately 50% the amplitude of the first); post-tetanic facilitation is present (twitches temporarily increase in amplitude after a tetanic stimulus); and a preceding dose of neostigmine produced temporary deepening rather than improvement. Which of the following correctly identifies the block type and explains how each monitored characteristic fits the pharmacological profile?

• A) The findings are consistent with Phase I (depolarizing) block — fade on TOF is the hallmark of Phase I block because persistent depolarization at the end plate progressively consumes acetylcholine stores with each sequential stimulus, and post-tetanic facilitation reflects the transient cholinergic surge after tetanic stimulation that partially overcomes persistent depolarization; neostigmine deepens the block because it inhibits pseudocholinesterase, prolonging succinylcholine's depolarizing action.
• B) The findings are consistent with non-depolarizing block from an unrecognized second agent — TOF fade and post-tetanic facilitation are pathognomonic for competitive receptor antagonism; the prior neostigmine dose deepened block transiently because the patient was inadvertently in a succinylcholine Phase I state at that moment, creating a combined depolarizing-competitive block that reversed the expected neostigmine effect.
• C) The findings are inconclusive — TOF fade is seen in both Phase I and Phase II block; post-tetanic facilitation cannot be interpreted without knowing the exact tetanic frequency used; and the neostigmine response is unreliable because its effect on succinylcholine-related block depends on the plasma pseudocholinesterase activity at the time of administration, which varies widely between patients.
• D) The findings are consistent with Phase II (dual) block — TOF fade indicates that the block has transitioned from the no-fade pattern of Phase I depolarizing block to the fade pattern characteristic of Phase II; post-tetanic facilitation is present in Phase II block as in non-depolarizing block; and neostigmine deepening rather than reversal is a defining clinical feature of Phase II block because neostigmine inhibits residual pseudocholinesterase, prolonging succinylcholine exposure and worsening the block; the correct management is supportive ventilation, not further reversal attempts.
• E) The findings are consistent with a mixed depolarizing and non-depolarizing block pattern produced by succinylcholine-induced Phase I block coexisting with spontaneous onset of non-depolarizing block as succinylcholine is metabolized; the TOF fade and post-tetanic facilitation reflect the emerging non-depolarizing component, and neostigmine deepened the residual Phase I component while reversing the non-depolarizing component, producing the net paradoxical worsening observed.

7. Two patients each receive a vecuronium infusion for 72 hours of ICU paralysis. Patient A has isolated hepatic failure from acetaminophen toxicity (normal renal function). Patient B has isolated acute kidney injury from contrast nephropathy (normal hepatic function). Which patient is at greater risk of prolonged block after infusion discontinuation, and which pharmacokinetic mechanism explains the risk?

• A) Patient B — the patient with acute kidney injury — is at greater risk, because vecuronium's principal route of elimination for its active metabolite is renal: hepatic deacetylation of vecuronium produces the 3-desacetyl metabolite retaining approximately 50% of the parent compound's neuromuscular blocking potency, and this active metabolite is eliminated renally; in Patient B, renal failure prevents its excretion and it accumulates to concentrations sufficient to sustain profound block for days after the vecuronium infusion is stopped, whereas Patient A's intact kidneys excrete the metabolite normally despite impaired parent drug hepatic metabolism.
• B) Patient A — the patient with hepatic failure — is at greater risk, because vecuronium's primary elimination pathway is renal excretion of unchanged parent drug; hepatic failure reduces first-pass hepatic extraction, which is normally complete in a single pass through the liver; preserved renal function in Patient A cannot compensate for the complete loss of hepatic extraction, leading to prolonged parent drug accumulation.
• C) Both patients are at equivalent risk of prolonged block, because vecuronium's elimination depends equally on hepatic metabolism and renal excretion of the parent compound; loss of either pathway alone reduces clearance by exactly 50%, producing equivalent duration prolongation regardless of which organ is impaired.
• D) Neither patient is at significant risk of prolonged block because vecuronium undergoes organ-independent Hofmann elimination as a secondary pathway that becomes the dominant route when both hepatic metabolism and renal excretion are compromised; with only one organ failing in each patient, sufficient alternative clearance capacity remains to prevent clinically significant accumulation.
• E) Patient A — the patient with hepatic failure — is at greater risk because the 3-desacetyl metabolite of vecuronium is produced by hepatic deacetylation and cannot be generated when hepatic function is absent; the absence of this active metabolite in Patient A paradoxically prolongs block because the parent vecuronium molecule — which has higher intrinsic potency than the metabolite — accumulates without being converted to the lower-potency metabolite form that would otherwise reduce effective receptor occupancy.

8. A 64-year-old man has been in the medical ICU for 12 days with severe sepsis. He has been sedated and mechanically ventilated throughout, with minimal movement of his extremities. He has no stroke, spinal cord injury, or burn history. He requires urgent reintubation for a mucus plug. An ICU nurse asks the physician whether succinylcholine can be safely used for rapid sequence intubation in this patient. Which of the following correctly integrates the pathophysiology of extrajunctional receptor upregulation in prolonged critical illness to answer this question?

• A) Succinylcholine is safe in this patient because extrajunctional nAChR upregulation requires a specific neurological injury to the motor neuron or its axon; prolonged immobilization and sedation in an ICU patient with intact innervation does not trigger extrajunctional receptor expression regardless of duration, so the muscle surface nAChR distribution remains normal and succinylcholine-induced potassium efflux is confined to the junctional zone as in any healthy patient.
• B) Succinylcholine is safe after 12 days of ICU immobilization because extrajunctional upregulation requires a minimum of 21 days of disuse before receptor density increases sufficiently to produce a clinically dangerous potassium surge; the risk begins only at 3 weeks and reaches its maximum at 6 weeks, making this patient's 12-day course below the threshold for significant concern.
• C) Succinylcholine poses a genuine hyperkalemia risk in this patient — prolonged immobilization and critical illness (particularly sepsis with its associated inflammatory state and disuse of skeletal muscle over more than 7 days) can drive extrajunctional nAChR upregulation by a mechanism analogous to denervation, even without an overt neurological injury; after 12 days of ICU immobilization with sepsis, sufficient extrajunctional receptor upregulation may have occurred to produce a clinically dangerous potassium efflux when succinylcholine activates the entire sarcolemmal surface, and succinylcholine should be avoided in favor of rocuronium with sugammadex available.
• D) Succinylcholine is absolutely contraindicated in all ICU patients regardless of duration of stay because critically ill patients invariably have serum potassium above 5.5 mEq/L from the catabolic and inflammatory state of critical illness, and succinylcholine's normal 0.5 mEq/L potassium rise is additive with the pre-existing hyperkalemia, always producing a total potassium sufficient to cause ventricular arrhythmias.
• E) The risk depends entirely on whether the patient has received any corticosteroids during his ICU stay — corticosteroids suppress the inflammatory cytokine-mediated signal that drives extrajunctional receptor upregulation in critical illness; a patient treated with corticosteroids has no extrajunctional upregulation regardless of duration, while an untreated patient develops full upregulation within 48 to 72 hours of sepsis onset.

9. A 35-year-old woman is found to have a dibucaine number of 22 after prolonged block following succinylcholine administration during an elective procedure. Her family asks whether her children should be tested for malignant hyperthermia susceptibility given this finding, and whether the dibucaine number result tells them anything about MH risk. Which of the following correctly integrates the genetics of pseudocholinesterase deficiency and malignant hyperthermia to answer this question?

• A) The dibucaine number of 22 confirms homozygous pseudocholinesterase deficiency, which is caused by the same RYR1 gene locus that governs malignant hyperthermia susceptibility in approximately 30% of affected families; the children should undergo both dibucaine number testing and ryanodine receptor genetic screening, as the two conditions are allelic variants of the same underlying calcium-handling disorder at the sarcolemmal level.
• B) A dibucaine number of 22 identifies homozygous atypical pseudocholinesterase deficiency and also confirms malignant hyperthermia susceptibility, because both conditions result from mutations that impair calcium-dependent membrane enzyme function; families carrying pseudocholinesterase mutations should always be screened for MH because the co-inheritance rate exceeds 40% in affected kindreds.
• C) The dibucaine number is not a useful screening tool because it reflects total plasma cholinesterase activity rather than enzyme structural variants, and a low value of 22 may represent either genetic deficiency or acquired pseudocholinesterase depletion from liver disease, malnutrition, or pregnancy; without genetic confirmation of the Asp70Gly substitution, no inference about MH risk or heritability can be drawn from a dibucaine number alone.
• D) A dibucaine number of 22 indicates that this patient carries a succinylcholine sensitivity mutation that co-segregates with malignant hyperthermia susceptibility in 15% of cases; the children should be referred for caffeine-halothane contracture testing of skeletal muscle, which detects both pseudocholinesterase deficiency and RYR1-mediated calcium dysregulation in a single assay.
• E) The dibucaine number result and malignant hyperthermia susceptibility are entirely independent — pseudocholinesterase deficiency results from mutations in the BCHE gene encoding butyrylcholinesterase, a plasma enzyme, while MH susceptibility results from mutations in the RYR1 gene encoding the skeletal muscle sarcoplasmic reticulum calcium release channel; the two genes are on different chromosomes, the two conditions have no established genetic linkage, and a dibucaine number of any value provides no information about MH risk; MH susceptibility testing requires either caffeine-halothane contracture testing of a muscle biopsy or direct RYR1 genetic sequencing.

10. A residency program director asks a trainee to explain why sugammadex has largely replaced neostigmine for reversal of rocuronium and vecuronium block in modern anesthesia practice, despite neostigmine being safe, inexpensive, and effective for decades. Which of the following best integrates the pharmacological limitations of neostigmine and the advantages of sugammadex to answer this question?

• A) Neostigmine has been replaced primarily because it requires co-administration of an anticholinergic agent to prevent bradycardia, and the anticholinergic agents available (atropine, glycopyrrolate) carry their own adverse effect profiles including tachycardia and urinary retention; sugammadex does not require anticholinergic co-administration, eliminating a two-drug regimen and its associated complications in a single step.
• B) Neostigmine has a fundamental pharmacological ceiling — it works by inhibiting acetylcholinesterase to raise acetylcholine concentration, but the maximum acetylcholine increase achievable is limited; at deep levels of block where receptor occupancy by the non-depolarizing agent is high, this ceiling acetylcholine concentration is insufficient to competitively displace enough blocking agent to restore adequate neuromuscular function, so neostigmine cannot reliably reverse deep or profound block; sugammadex works by encapsulating and removing rocuronium or vecuronium molecules from the plasma — a mechanism with no ceiling — and reliably reverses any depth of aminosteroid block including profound block (train-of-four count zero, post-tetanic count zero) with appropriate dosing, which neostigmine cannot do under any circumstances.
• C) Neostigmine has been replaced primarily because it inhibits both acetylcholinesterase and butyrylcholinesterase, and the latter inhibition prolongs succinylcholine block in patients who receive it for RSI; since most modern anesthetic techniques use rocuronium for RSI, the pseudocholinesterase inhibition of neostigmine creates a dangerous drug interaction that sugammadex avoids because it does not inhibit any esterase.
• D) Neostigmine's principal disadvantage compared to sugammadex is its slower speed of onset — neostigmine requires 10 to 15 minutes to reach peak effect even at maximum dose, during which time the patient must remain intubated and ventilated; sugammadex achieves full reversal within 60 to 90 seconds at all block depths, and this speed difference rather than any ceiling effect is the primary pharmacological reason for sugammadex's adoption as the preferred reversal agent.
• E) Neostigmine has been replaced because it produces a transient paradoxical deepening of block in the first 90 seconds after administration — caused by the sudden increase in synaptic acetylcholine activating presynaptic autoreceptors that reduce further acetylcholine release — which creates a brief window of complete paralysis before the net reversal effect develops; this paradoxical phase is dangerous in patients with borderline respiratory reserve, and sugammadex does not produce any paradoxical deepening.

11. A 72-year-old man with glaucoma has been using echothiophate iodide ophthalmic drops — a long-acting organophosphate anticholinesterase used to reduce intraocular pressure — for 6 months. He presents for cataract surgery and the anesthesiologist administers succinylcholine 1.5 mg/kg for intubation. Three hours later, the patient remains apneic and deeply paralyzed despite the expected 8 to 12 minute succinylcholine block. Which of the following correctly integrates the mechanism of this drug interaction?

• A) Echothiophate competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction — its ophthalmic absorption produces systemic concentrations sufficient to occupy a fraction of end-plate receptors; when succinylcholine is added, the combined competitive and depolarizing block at already-partially-occupied receptors produces a synergistic block of unpredictable duration.
• B) Echothiophate is metabolized by plasma pseudocholinesterase into an active intermediate that directly activates nicotinic receptors at the neuromuscular junction; when succinylcholine is given, it competes with this active metabolite for receptor binding, but the metabolite's higher affinity means it cannot be displaced, producing a mixed block that neostigmine paradoxically worsens.
• C) Echothiophate increases the plasma concentration of acetylcholine by inhibiting acetylcholinesterase in the synaptic cleft; the elevated synaptic acetylcholine desensitizes the end-plate nicotinic receptor before succinylcholine is administered, and the pre-desensitized receptor transitions to Phase II block more rapidly than usual, converting the expected brief Phase I block into immediate Phase II block lasting several hours.
• D) Echothiophate is a long-acting irreversible organophosphate inhibitor of cholinesterases; despite being administered topically to the eye, it achieves sufficient systemic absorption to irreversibly inhibit plasma pseudocholinesterase throughout the body; with pseudocholinesterase activity near zero, succinylcholine cannot be hydrolyzed and accumulates in the plasma for hours, producing a scoline apnea syndrome pharmacologically equivalent to homozygous pseudocholinesterase deficiency; recovery requires supportive ventilation until succinylcholine is eliminated by non-enzymatic routes over many hours.
• E) Echothiophate selectively inhibits plasma pseudocholinesterase by a reversible competitive mechanism, temporarily reducing enzyme activity by approximately 40%; this degree of inhibition extends succinylcholine duration from 8 to 12 minutes to approximately 20 to 30 minutes — equivalent to the heterozygous pseudocholinesterase deficiency phenotype — and the 3-hour apnea in this case reflects an idiosyncratic drug sensitivity rather than the expected pharmacological interaction.

12. A hospital pharmacy proposes removing succinylcholine from the formulary entirely, arguing that rocuronium 1.2 mg/kg plus sugammadex 16 mg/kg on standby provides equivalent RSI capability with fewer adverse effects. An anesthesiologist is asked to evaluate the proposal. Which of the following best integrates the pharmacological comparison of the two RSI strategies to assess this claim?

• A) The rocuronium-sugammadex RSI strategy is pharmacologically equivalent to succinylcholine for most RSI scenarios — rocuronium 1.2 mg/kg achieves intubating conditions within 45 to 60 seconds comparable to succinylcholine, and the immediate availability of sugammadex 16 mg/kg addresses the "cannot intubate, cannot oxygenate" scenario that historically made succinylcholine's short duration essential; however, succinylcholine retains practical advantages in settings where sugammadex may not be immediately available, where the cost of 16 mg/kg sugammadex is prohibitive, or where the clinical context genuinely requires the shortest possible duration of complete paralysis — such as electroconvulsive therapy or laryngospasm treatment — making complete formulary removal premature without system-level safeguards ensuring sugammadex availability at every RSI location.
• B) The proposal is pharmacologically sound and complete removal of succinylcholine is appropriate — rocuronium at 1.2 mg/kg has a faster onset than succinylcholine at 1.5 mg/kg, produces deeper and more reliable intubating conditions across a wider range of patient physiologies, and the rocuronium-sugammadex combination eliminates all the adverse effects of succinylcholine including malignant hyperthermia, hyperkalemia, myalgia, and bradycardia without introducing any new risks; no clinical scenario exists in which succinylcholine would be preferred over this combination.
• C) The proposal is not pharmacologically viable because rocuronium at 1.2 mg/kg does not reliably produce intubating conditions within the 60-second window required for RSI — its onset is 2 to 3 minutes regardless of dose, and the 45-second onset described in studies represents laryngeal muscle relaxation only, which is insufficient for safe laryngoscopy without complete abdominal muscle relaxation.
• D) Succinylcholine should be retained as the sole RSI agent and rocuronium removed from RSI protocols — rocuronium 1.2 mg/kg produces a clinical duration of 60 to 90 minutes that cannot be shortened to less than 15 minutes even with full sugammadex dosing, meaning that a failed intubation managed with this technique will leave the patient paralyzed and unventilatable for a minimum of 15 minutes before adequate spontaneous ventilation returns.
• E) The pharmacological equivalence depends entirely on the patient's pseudocholinesterase genotype — in patients with normal pseudocholinesterase, rocuronium-sugammadex and succinylcholine are equivalent; but in patients with heterozygous pseudocholinesterase deficiency, succinylcholine's duration extends to 20 to 30 minutes, making rocuronium-sugammadex pharmacologically superior; formulary decisions should therefore require pseudocholinesterase genotyping of all surgical patients before succinylcholine can be used.

13. A patient is extubated at the end of a 2-hour procedure with a quantitatively measured train-of-four (TOF) ratio of 0.72. In the post-anesthesia care unit 20 minutes later, she develops oxygen saturation of 88% despite 4 L/min nasal cannula oxygen, produces a weak ineffective cough when she attempts to clear secretions, and a nasopharyngoscopy reveals pooling of secretions above the larynx with impaired swallowing. Which of the following correctly integrates the clinical consequences of a TOF ratio of 0.72 and explains why the pharyngeal findings are disproportionate to her apparent ability to sustain spontaneous breathing?

• A) A TOF ratio of 0.72 indicates complete recovery of neuromuscular function — values above 0.7 represent the normal range of variability in conscious volunteers and do not indicate residual block; the pharyngeal findings and hypoxia in this patient must be attributed to residual volatile anesthetic or opioid effect rather than neuromuscular block, as the TOF ratio confirms adequate neuromuscular reversal.
• B) A TOF ratio of 0.72 indicates moderate residual block affecting all skeletal muscles equally — diaphragmatic, intercostal, pharyngeal, and laryngeal muscles are all depressed to the same degree; the patient's ability to breathe spontaneously reflects the large respiratory reserve of normal lungs rather than differential muscle sensitivity, and her hypoxia reflects global hypoventilation rather than upper airway dysfunction.
• C) A TOF ratio of 0.72 indicates clinically significant residual neuromuscular block; pharyngeal and upper esophageal sphincter muscles are disproportionately sensitive to partial neuromuscular block compared to the diaphragm — they lose coordinated function at TOF ratios below 0.9 while the diaphragm can sustain adequate tidal volumes at lower ratios; this differential sensitivity explains why the patient can breathe but cannot protect her airway, pool secretions above the larynx, and develops hypoxia from aspiration or upper airway obstruction rather than from global hypoventilation; full recovery requires a TOF ratio of at least 0.9.
• D) A TOF ratio of 0.72 reflects a measurement artifact caused by electrode displacement in the post-anesthesia care unit — the true TOF ratio is likely above 0.9 because the patient is spontaneously breathing; the pharyngeal dysfunction is caused by the intubation itself producing post-extubation laryngeal edema and mucosal irritation, not by residual pharmacological neuromuscular block at a TOF ratio above 0.7.
• E) The TOF ratio of 0.72 is consistent with deep residual block equivalent to a TOF count of 1 — ratios between 0.7 and 0.8 in quantitative monitoring correspond to the same clinical state as a TOF count of 1 on qualitative assessment; this depth of block is associated with complete loss of all voluntary muscle function including diaphragmatic ventilation, and the patient's ability to breathe spontaneously indicates that the acceleromyographic monitoring device was miscalibrated.